Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: results of a prospective randomized trial
/in Colorectal Cancer, International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2008-05-17 / Cancer Immunol. Immunother. 2009 Jan;58(1):61-9An effective tumor vaccine optimized for costimulation via bispecific and trispecific fusion proteins
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2008-04-01 / Int. J. Oncol. 2008 Apr;32(4):777-89Brain tumor therapy by combined vaccination and antisense oligonucleotide delivery with nanoparticles
/in International Publications, Newcastle Disease Virus /von 2008-03-04 / J. Neuroimmunol. 2008 Mar;195(1-2):21-7Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses
/in International Publications, Newcastle Disease Virus /von 2008-02-15 / Biochim. Biophys. Acta 2008 Apr;1785(2):217-31Second International Conference on Cancer Vaccines/Adjuvants/Delivery for the Next Decade (CVADD): Heidelberg, Germany, 10-12 October 2007
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2008-02-13 / Cancer Immunol. Immunother. 2008 Sep;57(9):1421-7Generation of a recombinant oncolytic Newcastle disease virus and expression of a full IgG antibody from two transgenes
/in International Publications, Newcastle Disease Virus /von 2008-01-17 / Gene Ther. 2008 Mar;15(5):371-83Host mediated anti-tumor effect of oncolytic Newcastle disease virus after locoregional application
/in International Publications, Newcastle Disease Virus /von 2007-11-01 / Int. J. Oncol. 2007 Nov;31(5):1009-19Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy
/in International Publications, Newcastle Disease Virus /von 2007-10-04 / Gene Ther. 2007 Dec;14(23):1639-49Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus
/in International Publications, Newcastle Disease Virus /von 2007-09-01 / Cancer Res. 2007 Sep;67(17):8285-92
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- From Localized Mild Hyperthermia to Improved Tumor Oxygenation: Physiological Mechanisms Critically Involved in Oncologic Thermo-Radio-Immunotherapy
- Individualized Multimodal Immunotherapy for Adults with IDH1 Wild-Type GBM: A Single Institute Experience
- Immunotherapy in breast cancer: an overview of current strategies and perspectives